

PCIF1 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP5063a**Specification**

PCIF1 Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [Q9H4Z3](#)**PCIF1 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 63935**Other Names**

Phosphorylated CTD-interacting factor 1, PCIF1, C20orf67

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PCIF1 Antibody (N-term) Blocking Peptide - Protein Information**Name** PCIF1 {ECO:0000303|PubMed:12565871, ECO:0000312|HGNC:HGNC:16200}**Function**

Cap-specific adenosine methyltransferase that catalyzes formation of N(6),2'-O-dimethyladenosine cap (m6A(m)) by methylating the adenosine at the second transcribed position of capped mRNAs (PubMed:30467178, PubMed:30487554, PubMed:31279658, PubMed:31279659, PubMed:33428944). Recruited to the early elongation complex of RNA polymerase II (RNAPII) via interaction with POLR2A and mediates formation of m6A(m) co-transcriptionally (PubMed:30467178).

Cellular Location

Nucleus

Tissue Location

Ubiquitous..

PCIF1 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

PCIF1 Antibody (N-term) Blocking Peptide - Images

PCIF1 Antibody (N-term) Blocking Peptide - Background

PCIF1 may play a role in transcription elongation or in coupling transcription to pre-mRNA processing through its association with the phosphorylated C-terminal domain (CTD) of RNAPII largest subunit.

PCIF1 Antibody (N-term) Blocking Peptide - References

Yunokuchi, I., et al. Genes Cells 14(9):1105-1118(2009)Kathiresan, S., et al. Nat. Genet. 41(1):56-65(2009)Hirose, Y., et al. Biochem. Biophys. Res. Commun. 369(2):449-455(2008)